StockData

Johnson & Johnson vs Eli Lilly

JNJ and LLY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JNJ and LLY compare

Eli Lilly is the larger company, worth 2.0 times as much as Johnson & Johnson ($1.3T against $671B).

On earnings, Johnson & Johnson is cheaper: it trades at 42.3× trailing earnings, against 45.9× for Eli Lilly.

Eli Lilly grew revenue faster over the last twelve months (45.5% versus 7.8% for Johnson & Johnson).

Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 16.2% at Johnson & Johnson.

Both pay dividends: Johnson & Johnson yields 1.9% and Eli Lilly 0.37%.

Eli Lilly scores higher on the StockData Score (19 against 12 for Johnson & Johnson), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJNJLLY
Size and price
Market cap$671B$1.3T
Share price$278.70$1415.55
Change, 1 year42.2%38.1%
Change, 5 years75.1%444%
Beta (5Y)−0.300.28
Employees138K50K
StockData Score
Total score1219 (better)
Valuation score02 (better)
Growth score35 (better)
Performance score45 (better)
Health score34 (better)
Dividend score23 (better)
Valuation
P/E42.3× (better)45.9×
P/S6.8× (better)15.4×
P/B8.2× (better)33.1×
EV/EBITDA26.0× (better)37.3×
P/FCF32.6×–
PEG2.360.93 (better)
FCF yield3.1%–
Fair value$150.10$1131.93
Margin of safety−85.7%−25.1% (better)
Growth
Revenue growth (TTM)7.8%45.5% (better)
Revenue growth, 5Y average2.7%21.6% (better)
Net income growth (TTM)−35.9%49.8% (better)
EPS growth (TTM)−36.4%50.7% (better)
EPS growth, 5Y average14.9%27.6% (better)
Profitability
Gross margin67.6%83.6% (better)
Net margin16.2%31.9% (better)
FCF margin20.7%–
Return on equity20.0%86.1% (better)
Financial health
Debt / equity0.55 (better)1.23
Net debt / EBITDA1.02 (better)1.21
Current ratio1.021.39 (better)
Altman Z-score5.188.50 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Dividend yield1.9% (better)0.37%
Payout ratio–21.7%
Years of dividend growth16 (better)9
Dividend growth, 5Y average5.2%15.2% (better)
Buyback yield1.2% (better)0.44%
Shareholder yield3.1% (better)0.81%
Ownership
Held by institutions74.8%83.8%
Held by insiders0.04%10.4%
Insider net buying, 12 months−$154M (better)−$373M
Superinvestors holding6 (better)3
Short interest, % of float0.71%0.86%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.